Daewon Pharmaceutical Co., Ltd. (KRX:003220)
South Korea · Delayed Price · Currency is KRW 7,710.00
-100.00 (-1.28%)
At close: Aug 21, 2026
Daewon Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 165,252 | 256,130 | 305,427 | 331,930 | 393,197 | 342,999 | |
Market Cap Growth | -40.56% | -16.14% | -7.99% | -15.58% | 14.64% | -9.91% |
Enterprise Value | 296,270 | 409,009 | 434,054 | 418,509 | 453,068 | 412,231 |
Last Close Price | 7710.00 | 11950.00 | 13957.75 | 15014.55 | 17630.58 | 14913.94 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 39.94 | - | 21.49 | 13.88 | 12.31 | 49.08 |
Forward PE | 7.35 | 73.09 | 8.31 | 9.94 | 11.36 | 16.53 |
PS Ratio | 0.27 | 0.42 | 0.51 | 0.63 | 0.82 | 0.97 |
PB Ratio | 0.60 | 0.93 | 1.07 | 1.26 | 1.58 | 1.57 |
P/TBV Ratio | 0.82 | 1.12 | 1.27 | 1.37 | 1.74 | 1.77 |
P/FCF Ratio | - | 20.47 | - | 8.41 | 21.36 | 18.73 |
P/OCF Ratio | 9.09 | 6.05 | 10.17 | 6.42 | 14.89 | 15.30 |
PEG Ratio | - | 1.87 | 0.47 | 2.49 | 0.49 | 0.49 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.48 | 0.68 | 0.73 | 0.79 | 0.95 | 1.16 |
EV/EBITDA Ratio | 10.60 | 15.02 | 9.28 | 8.40 | 7.28 | 11.11 |
EV/EBIT Ratio | 88.54 | 117.39 | 16.27 | 12.98 | 10.56 | 21.36 |
EV/FCF Ratio | - | 32.69 | - | 10.61 | 24.62 | 22.52 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.69 | 0.74 | 0.66 | 0.55 | 0.47 | 0.57 |
Debt / EBITDA Ratio | 7.72 | 7.42 | 4.00 | 2.93 | 1.87 | 3.34 |
Debt / FCF Ratio | - | 16.15 | - | 3.70 | 6.33 | 6.77 |
Net Debt / Equity Ratio | 0.45 | 0.46 | 0.50 | 0.44 | 0.28 | 0.32 |
Net Debt / EBITDA Ratio | 5.02 | 4.61 | 3.02 | 2.33 | 1.12 | 1.86 |
Net Debt / FCF Ratio | -23.78 | 10.04 | -29.22 | 2.94 | 3.78 | 3.78 |
Asset Turnover | 1.07 | 1.01 | 1.10 | 1.10 | 1.09 | 0.93 |
Inventory Turnover | 3.06 | 3.17 | 2.86 | 2.76 | 3.01 | 2.69 |
Quick Ratio | 0.60 | 0.72 | 0.62 | 0.56 | 0.89 | 1.07 |
Current Ratio | 1.12 | 1.19 | 1.19 | 1.15 | 1.62 | 1.77 |
Return on Equity (ROE) | 0.83% | -0.79% | 3.68% | 9.15% | 13.13% | 3.07% |
Return on Assets (ROA) | -0.01% | 0.36% | 3.06% | 4.19% | 6.07% | 3.16% |
Return on Invested Capital (ROIC) | -0.01% | -0.73% | 4.14% | 8.38% | 11.21% | 2.75% |
Return on Capital Employed (ROCE) | 0.00% | 0.90% | 7.00% | 9.90% | 13.20% | 5.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.59% | -0.54% | 4.65% | 7.21% | 8.12% | 2.04% |
FCF Yield | -3.13% | 4.88% | -1.58% | 11.88% | 4.68% | 5.34% |
Dividend Yield | 3.22% | 2.09% | - | - | - | 1.30% |
Payout Ratio | 203.58% | - | 44.75% | 30.69% | 12.90% | 44.93% |
Buyback Yield / Dilution | -0.00% | -0.67% | 1.71% | 0.98% | -3.09% | 0.58% |
Total Shareholder Return | 3.22% | 1.42% | 1.71% | 0.98% | -3.09% | 1.88% |